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The NIH Pharmacogenetics Research Network (PGRN) is a collaborative group of investigators with a wide range
of research interests, but all attempting to correlate drug response with genetic variation. Several research groups
concentrate on drugs used to treat specific medical disorders (asthma, depression, cardiovascular disease, addiction
of nicotine, and cancer), whereas others are focused on specific groups of proteins that interact with drugs (membrane
transporters and phase II drug-metabolizing enzymes). The diverse scientific information is stored and annotated in a
publicly accessible knowledge base, the Pharmacogenetics and Pharmacogenomics Knowledge base (PharmGKB). This
report highlights selected achievements and scientific approaches as well as hypotheses about future directions of each
of the groups within the PGRN. Seven major topics are included: informatics (PharmGKB), cardiovascular, pulmonary,
addiction, cancer, transport, and metabolism.
The explosive and simultaneous development of molecular
pharmacology, biotechnology, and genomics is revolutioniz-
ing basic principles of drug therapy and development.
Although the concept that an individual’s DNA sequence
could be an integral determinant of drug therapy has not yet
become a standard part of clinical medicine, progress in
linking inheritance to drug discovery and therapeutics has
been the topic of innumerable basic science reports, clinical
reviews, and articles in the lay press. The goal of
individualized drug therapy has already had a powerful
impact on key funding agencies such as the National
Institutes of Health (NIH) (e.g., the NIH Roadmap),
regulatory agencies such as the Food and Drug Administra-
tion (FDA) (e.g., 2003 Draft Guidance for Industry
Pharmacogenomic Data Submissions), and the pharmaceu-
tical and biotechnology industries (e.g., package insert for
irinotecan). Nonetheless, the critical element for moving the
relationship of drug therapy and genetics closer to the clinical
realm is solid scientific evidence and clear advice for the
practicing clinician on how to modify dosages or therapies
based on the results of pharmacogenetic tests.
The NIH Pharmacogenetics Research Network (PGRN)
functions as a collaborative team of multidisciplinary
research groups focused on a wide range of scientific
questions, but all that attempting to correlate drug response
phenotypes with genetic variation. Creating an infrastructure
that includes a network of investigators with complementary
areas of expertise generates an impetus to share resources,
tools, and statistical approaches. The research activity of
PGRN encompasses a variety of disorders, including asthma,
depression, cardiovascular disease, addiction to nicotine, and
cancer. Another major component of the PGRN focuses on
specific groups of proteins, membrane transporters, and
phase II drug-metabolizing enzymes, which have critical roles
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in drug absorption and elimination in patients with a wide
variety of disease states. Thus, the unifying, fundamental
focus of PGRN investigation is pharmacogenetics; aiming to
identify the genetic sources of interindividual variability in
response to drugs by using and exploiting diverse research
strategies. Finally, coordinating this diverse scientific activity
into a single, publicly accessible knowledge database,
Pharmacogenomics and Pharmacogenetics Knowledge base
(PharmGKB),1 remains an ongoing and vital function of the
PGRN. Such a knowledge base is likely to attain consistent
quality and significant depth with greater diversity than an
individual research team.
In drug development and therapy, the role of genetics
must be tied to both maximizing effective therapy and
avoiding adverse effects; recognizing that variable responses
are secondary to many overlapping factors that interact with
an individual’s genetic make-up (e.g., age, co-morbidities,
drug–drug interactions, environment, diet, etc). Although
currently there is a paucity of genetics-guided recommenda-
tions, eventually mainstream medicine will include targeted
drug therapies that will be prescribed based on genotypic
information. In this case, the cost of and morbidity from
drug toxicity or side effects will be minimized and efficacy
maximized.
Early pharmacogenetic research focused on obtaining
DNA from outliers in drug response (e.g., succinylcholine,
isoniazid) to identify inherited variation in one or few
enzymes that metabolized that particular drug. The sequen-
cing of the entire human genome created the foundation for
further studies to identify genetic factors that can be aligned
with drug response or toxicity. In the postgenomic era, the
ready availability of DNA sequencing via high-throughput
analyses has propelled the field of pharmacogenetics
beyond recognizing and defining abnormal phenotypes
(e.g., unexpected toxicity associated with a ‘‘normal’’ dose
of a drug) toward determining underlying molecular
mechanisms responsible for pharmacodynamics (PDs) and
pharmacokinetics (PKs) of drug therapy. For example,
samples from anonymized volunteers are screened for
common single-nucleotide polymorphisms (SNPs) and
haplotypes (combinations of SNPs within a contiguous
segment of DNA), and then these candidate variants are
searched within populations expressing an abnormal pheno-
type. Genome-wide association studies are now possible and
can link multiple SNPs and haplotypes to drug response with
no a priori assumptions, thereby facilitating new discoveries.
Eventually, from such complex data sets, objective data will
be gained that will serve as the basis for designing drug
therapy based on the specific molecular genetic profile of a
patient. However, interpreting this massive amount of data to
prospectively guide dosage and drug regimens will require
another level of integrated investigation, access to large
databases rich in well-defined phenotypic and genotypic data,
and systems to maintain patient confidentiality.
PGRN investigators employ three primary strategies to
identify genetic factors that associate with drug response. The
first strategy involves phenotype–to-genotype studies in
which SNPs in candidate genes are associated with variation
in drug response including adverse drug reactions. Candidate
genes are selected by constructing PK and PD pathway
diagrams for the drug (see Figure 1, for statins). SNPs in any
gene in the PK or PD pathways are candidates for association
with drug response. The second strategy involves genotype-
to-phenotype studies. In these controlled studies, individuals
with particular genotypes are given drugs and a drug
phenotype (e.g., QT interval) is measured to provide
powerful in vivo proof that an SNP is associated with a drug
response. The third strategy involves whole-genome analysis.
Here, investigators perform whole-genome association stu-
dies and/or linkage analysis, identifying portions of the
genome that contain genetic variants associated with a
specific phenotype. Several groups within PGRN use cell lines
from the International HapMap project that are rich in
genotypic information, whereas others perform these studies
on clinical samples from individuals. In some cases, these
SNPs or haplotypes may be causative, i.e., they may be
responsible for the mechanism of altered drug response. In
other cases, the SNPs or haplotypes are in linkage
disequilibrium with the actual causative SNP and further
studies will be needed to identify the causative SNPs. One
important caveat is the problem of multiple testing, resulting
in false positives. Therefore, strategies to corroborate initial
associations through replication in independent cohorts and/
or through assessment of a functional role of the associated
SNPs or haplotypes are critical.
The initial research groups within the PGRN were funded
for 5 years beginning in 2000. After competitive renewal,
three new projects were added in 2005. The intention of this
document is to highlight the achievements and approaches of
each of the research groups within the PGRN, including
hypotheses about future directions of the various collaborat-
ing groups within PGRN. There are seven major topics
including informatics (PharmGKB): cardiovascular, pulmon-
ary, addiction, cancer, transport, and metabolism. In this
overview, we present goals, findings, and future directions of
each of the research groups in the PGRN organized under the
seven major topics.
INFORMATICS
PharmGKB
Introduction. PharmGKB (http://www.pharmgkb.org/) is a
publicly available internet research tool1 that curates
information to establish knowledge about the relationships
among drugs, genes, and disease (Figures 2, 3), as described
in detail below. In spite of the wide range of projects included
in the PGRN, the PharmGKB serves as a central bank of data
that is readily accessible by investigators both within and
beyond the PGRN network and as a system to correlate
variant data with those in other databases (e.g., dbSNP,
HapMap, and jSNP). As a result, PharmGKB provides the
scientific and lay community with an integrated knowledge
base.
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Goals. The PharmGKB strives to establish the definitive
source of information about the interaction of genetic
variability and drug response in five primary ways. First,
primary genotyping data that are important for the PKs or
PDs of drugs are stored and presented in an organized and
clear format. Second, phenotype measures of drug response
at the molecular, cellular, and organismal level are correlated
with genotypic data. Third, curating the major findings of the
published literature in establishing gene–drug interactions
provides easy access to multiples areas of research. For
example, more than 1,500 articles in pharmacogenetics can
be accessed through PharmGKB. Fourth, providing informa-
tion about drug response pathways (both PK and PD) allows
visual integration of several different projects. Fifth,
PharmGKB highlights very important pharmacogenes (VIP
genes) that are critical for understanding pharmacogenomics,
including information on variant genes, drugs, diseases, and
pathways and phenotypes of drug response (Figure 1).
Findings and future directions. PharmGKB provides accu-
rate information about genetic variation in more than 200
genes important for PK or PD (Figure 3). This site hosts
more than 35,000 unique internet visitors per month and has
more than 2,100 registered users (who gain access to
individual level genotype and phenotype data). For example,
PharmGKB contains more than 1.2 million individual SNPs
measured in at least 13,000 subjects, corresponding to
multiple loci in the human genome showing variation. This
knowledge base provides visual and spreadsheet mapping of
SNPs (Figure 4) and links to other resources, such as dbSNP
and vendor genotyping platforms. Currently, the knowledge
base is a repository for data on more than 200 genes and their
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Figure 1 PD and PK pathways of HMGCo A reductase inhibitors (Statins). (a) Cholesterol and lipoprotein transport: genes involved in mediating statin effects
on hepatic cholesterol metabolism and consequent effects on plasma lipoprotein transport. Statins inhibit endogenous cholesterol production by
competitive inhibition of HMG-CoA reductase (HMGCR), the enzyme that catalyzes conversion of HMG-CoA to mevalonate, an early rate-limiting step in
cholesterol synthesis. This pathway delineates genes involved in statin pharmacogenomics, including genes involved in mediating the PD effects of statins on
plasma lipoprotein metabolism and those involved in the PKs effects of the drug transport and metabolism. Note the effects of inhibition of HMG-CoA
reductase on major aspects of hepatic cholesterol metabolism and selected gene products that can modulate the effects of statins on metabolism and
transport of plasma lipoproteins. (b) PKs of Statins: representation of the superset of all genes involved in the transport, metabolism, and clearance of statin
class drugs. This figure depicts a generalized view of the PKs of statins, representing the superset of all genes with a reported influence on statin transport
and metabolism. Statins are dosed orally and enter the systemic circulation through intestinal cells both passively and by active transport via the ABC and SLC
gene family transporters. The major organs of metabolism and elimination include the liver and, to a lesser extent, the kidney. Metabolism is catalyzed by
enzymes of the CYP and UGT gene family. The main pathway of elimination is ABC-transporter-mediated biliary excretion. The more hydrophilic compounds
(e.g., pravastatin) require active transport into the liver, are less metabolized by the CYP family, and exhibit more pronounced active renal excretion, whereas
the less hydrophilic compounds are transported by passive diffusion and are better substrates for both CYP enzymes and transporters involved in biliary
excretion. These figures are available at www.pharmgkb.org.
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variants and includes information on more than 300 diseases
and 400 drugs. Collaborating with investigators in the PGRN,
PharmGKB has established novel displays of drug response
pathways and specific pages summarizing data about VIP
genes that may facilitate research design and data analysis.
The site can be reached directly (http://www.pharmgkb.org/
search/annotatedGene/index.jsp) or via the main PharmGKB
site. As new directions of research and discovery evolve, this
site is updated.
PharmGKB is developing as an enhanced system for
annotating pharmacogenomic information, both contained
within PharmGKB and present in other data resources, in
order to allow users to conduct more powerful searches and
discovery of relevant datasets. As part of this effort,
PharmGKB is conducting studies to understand the primary
applications and anticipated requirements of those who
frequently access this site. PharmGKB is focusing on
integrating, aggregating, and annotating important data sets
for pharmacogenomics to catalyze this research, particularly
for investigators who are new to the area of genetics of drug
response.
PharmGKB can be accessed for in-depth analysis, detailed
data sets, and additional references for each of the topics
discussed below.
CARDIOVASCULAR
Pharmacogenomic Evaluation of Antihypertensive Responses
Introduction. Hypertension is a common, chronic disease,
affecting an estimated 65 million Americans.2 Although five
drug classes are available for the first-line treatment of
hypertension,3 only about a third of hypertensive patients
have their blood pressure (BP) controlled to o140/90 mm
Hg.3 The underlying mechanisms for this poor rate of
response to antihypertensives are unclear, but one contrib-
utory factor is that selecting an agent for an individual is
empiric, and any given antihypertensive drug is effective in
only about 50% of the population.4 Similar to the response to
the wide range of drugs available to treat other complex
polygenic diseases such as asthma and various arrhythmias,
genetic mechanisms are likely to contribute to the variable
response to antihypertensive agents.
Goals. The overriding goal of the Pharmacogenomic
Evaluation of Antihypertensive Responses (PEARs) is to
identify the genetic determinants of response to two major
antihypertensive drug classes, thiazide diuretics and b-
adrenergic-receptor blockers. As with other complex,
multifactorial diseases, the key tactic is correlating under-
lying genetic factors with carefully documented clinical
phenotypes to design rational, individualized antihyper-
tensive therapy and to base drug development on genetic
principles.
Although recent studies have suggested that genetic
variability influences the response to hydrochlorothiazide, a
thiazide diuretic, many genes seem to contribute to the
overall effect. For example, GNB3, WNK1¸ AGTR1, SCNN1G,
and NOS35–8 each seem to explain only a small portion
(o5%) of the response variability. Clearly, a more in-depth
analysis of genes involved in variable response to diuretics is
critical before such data can be rationally applied to predict
drug response to hydrochlorothiazide.
A similar challenge has been identified for b-blockers. The
b1-adrenergic receptor (ADRB1) may explain up to 20% of
the variable response to a b-blocker.9 For example, two of
four diplotype groups responded to metoprolol, but two did
not (Figure 5). Clearly, as with the thiazide diuretics,
establishing an algorithm that predicts poor or excellent
response based on genotype would dramatically promote
establishing an antihypertensive regimen tailored to a specific
patient. Not only is the genetic contribution to treatment of
hypertension incomplete, data about the genetic basis for
adverse metabolic responses to diuretics and b-blockers are
nonexistent. Metabolic side effects often limit the clinical use
of these drugs and contribute to noncompliance. Accurately
predicting which hypertensive patients are predisposed to
adverse events would also facilitate rational antihypertensive
therapy.
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Figure 2 The home page of PharmGKB provides a straightforward schema
for understanding pharmacogenomics. After drugs are delivered, PKs and
PDs both involve sets of genes and lead to both efficacious and toxic effects.
Variation in response can be related to the PK and PD genes by studying
their variations in the human population. All data in the PharmGKB are
indexed as being relevant to PK, PD, clinical outcomes (CO), genetic
variation (GN), or functional assays at the molecular and cellular level (FN).
Browse PharmGKB
Search PharmGKB:?
Variant genes Literature Drugs Pathways Diseases Phenotypes
110337364261,516
e.g., a gene ("CYP2C9"), drug ("tamoxifen"), or disease ("hypertension")
230
Go
Figure 3 Browsing function in PharmGKB. PharmGKB allows users to
browse the major classes of data (genetic variation in pharmacogenes,
curated literature, drugs associated with genotype, phenotype, pathway or
other information, pathways, diseases, and phenotype data files). The
number of data objects in each category is displayed, and there is a full-text
search capability to allow more focused searching.
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Future directions. As PEAR is one of three newly funded
centers in the PGRN, a description of approaches, rather than
findings, follows. PEAR is a research group primarily focused
on an 800-subject clinical study enrolling patients with
mild to moderate hypertension, including approximately
45% African Americans. Key aspects of this effort are that all
antihypertensive drugs will be discontinued, followed by
re-defining the profile of each patient’s hypertension by
collecting BP data both at home and at a clinic. Because a
high-quality, reproducible phenotype in genetic association
studies is critical, focusing on home and ambulatory BP over
the clinic BP is especially important in these initial efforts to
establish a reliable, less variable phenotype of uncomplicated,
mild-to-moderate hypertension.10–12 Along with precisely
defining the clinical phenotype, blood and urine samples will
be collected for genetic and biomarker studies. Transformed
lymphocyte cell lines will be created for other genetic in vitro
investigations.
Patients will be randomized to receive either atenolol
50 mg daily or hydrochlorothiazide 12.5 mg daily, with one
dose-doubling step, after which the BP profile will be
repeated. In those patients whose BP remains greater than
120/70 mm Hg (expected to be 495% of the study
population), the other antihypertensive agent will be added,
with a similar dose-doubling step for BP 4120/70 mm Hg,
followed by an additional collection of the BP profile.
The hypothesis in PEAR is that genetic polymorphisms
influence the antihypertensive and adverse metabolic re-
sponses to atenolol and hydrochlorothiazide. Candidate gene
and whole-genome approaches will be combined in an
attempt to define a predictive model for response to these
two pharmacologically distinct agents. The candidate gene
studies will include 70 genes, using a tag SNP approach to
Figure 4 Example of the PharmGKB gene variant browser: nitric oxide synthetase 3 (NOS3). NOS3 is involved in the angiotensin and vascular endothelial
growth factor (agents inhibiting the vascular endothelial growth factor signaling pathway have been developed as a new class of anticancer agents)
pathways and the response to a number of drugs. The genomic DNA is the thick bar, with exons marked in brown. SNPs in PharmGKB are shown above the
genomic DNA with a graphical indication of minor allele frequency. The location of SNPs in dbSNP and jSNP are shown below the genomic DNA. The table
shows the chromosomal position, with links to the Golden Path genome browser, dbSNP, and with links to detailed information about the alleles, assays,
frequencies, and individual-level data.
Figure 5 Diastolic blood pressure response to metoprolol in hypertensive
patients is predicted by ADRB1 diplotype. Diplotype is defined by the SNPs
at codons 49 and 389. SR¼ Ser49Arg389; SG¼ Ser49Gly389;
GR¼Gly49Arg389. Reproduced from Clinical Pharmacology and
Therapeutics 37, 44–52 (2003).
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identify variability in the gene. The primary BP response
phenotype will be defined according to home BP measure-
ments, and the primary metabolic response phenotypes will
be insulin sensitivity and change in plasma triglycerides. The
BP response–genetic associations will include analyses of
responses to monotherapy, add-on therapy, and the combi-
nation of the two drugs. This candidate gene approach will be
supplemented through genome-wide associations.
Given that the response to b-blockers is strongly
correlated with that of angiotensin-converting enzyme
inhibitors and angiotensin-receptor blockers, and diuretic
response is strongly correlated with calcium channel blocker
response, these studies may also provide insights into the
genes involved in responses to the other first-line anti-
hypertensive drug classes.
Pharmacogenomics and Risk of Cardiovascular Disease
Introduction. Although statins are the most prescribed class
of drugs worldwide, and therapy with these drugs is generally
associated with a reduction in risk for cardiovascular events
by 20–30%, clinical response can be highly variable and
adverse drug responses are well described. In fact, as many as
30% of patients do not achieve the lipid-lowering goals set
before onset of therapy. Six statins are currently marketed in
the United States, including atorvastatin, simvastatin, rosu-
vastatin, pravastatin, fluvastatin, and lovastatin. These
statins all target HMGCoA reductase, but differ in terms of
their potencies and PK properties. Dose-limiting side effects
include myopathies and liver function abnormalities. Rhab-
domyolysis is a rare, but serious adverse effect of this class of
drugs.
Goals. The overall objective of the project Pharmacoge-
nomics and Risk of Cardiovascular Disease (PARC) is to
identify genetic determinants of the wide range of inter-
individual variability in phenotypic and clinical response to
statins. A key feature is the use of multiple statin-treated
population samples to test the reproducibility and general-
izability of findings derived from both candidate gene and
genome-wide searches for SNP associations with markers of
statin efficacy as well as muscle toxicity.
Findings and future directions. In a group of 944 African-
American and European-American subjects, treatment with
simvastatin was associated with variable response in levels of
lipid and lipoproteins. Of note, European Americans had a
greater low-density lipoprotein reduction and a slightly
greater increase in high-density lipoprotein. Older subjects,
women, and nonsmokers had a greater decrease in low-
density lipoprotein cholesterol.13
In this study population, the magnitude of statin-induced
low-density lipoprotein cholesterol reduction was associated
with a common haplotype in the HMGCoA reductase
gene.14 This haplotype also has been reported to be associated
with low-density lipoprotein response in a second inde-
pendent study population, in which a different statin was
administered (pravastatin);15 this population is now
being further studied in PARC. Such replication of results
is not frequently observed in pharmacogenetic studies.
Moreover, the minor allele of this haplotype, in combination
with a second haplotype in HMGCoA reductase, was
found to contribute significantly to reduced statin efficacy
in African Americans.13,14 The SNPs in both of these
haplotypes are exclusively in non-coding regions, and
evidence has been obtained that variation in transcriptional
regulation of HMGCoA reductase may underlie this
genetic effect on statin response (Medina M and Krauss
RM, unpublished).
A genome-wide SNP association study, with replication of
significant findings in a total of four study populations
treated with various statins, is currently underway to provide
a more comprehensive analysis of the contribution of genetic
polymorphisms to variation in statin response. Future goals
include testing for associations of the most informative SNPs
with clinical cardiac end points in several of the largest statin
trials. In addition, studies utilizing a genome-wide SNP panel
along with candidate gene SNPs are aimed at identifying
genetic susceptibility to statin-related myopathy. PARC
presents a comprehensive approach for determining effects
of specific genotypes on clinically meaningful variations in
responsiveness to the class of drugs most widely used to
prevent cardiovascular disease.
Pharmacogenomics of Arrhythmia Therapy
Introduction. Sudden cardiac death due to ventricular
fibrillation accounts for about 20% of all deaths in US
adults, about 400,000/year,16 and atrial fibrillation (AF), a
major cause of stroke, affects 2,000,000–5,000,000 Amer-
icans.17 In some cases, drugs successfully treat arrhythmias,
but the effects of antiarrhythmics are unpredictable in an
individual patient; indeed, commonly used antiarrhythmic
drugs can themselves elicit fatal rhythm disturbances in some
patients.18 One well-described ‘‘proarrhythmia’’ syndrome
includes marked prolongation of the QT interval on the
surface electrocardiogram. This rhythm is particularly high
risk because it can elicit the potentially fatal ventricular
arrhythmia, torsades de pointes.19 Marked QT prolongation
(and torsades de pointes) has been clearly associated with the
well-described congenital long QT syndromes and also has
been induced by a variety of antiarrhythmics. In addition,
exposure to certain non-cardiovascular drugs (e.g., certain
antipsychotics, erythromycin) may also elicit long QT
syndrome. These and other causes of sudden cardiac death
can be effectively managed by implanting cardioverter/
defibrillator devices.20,21 In fact, non-pharmacologic thera-
pies (e.g., implanting a cardioverter/defibrillator device,
ablation procedures) have evolved, in part, secondary to the
limited efficacy and proarrhythmic side effects of antiar-
rhythmics. As the concepts of pharmacogenetics evolve to
fine-tune the process of individualized drug selection, better
pharmacologic options may become available to patients at
risk for sudden cardiac death.
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Goals. The overall hypothesis of the Pharmacogenomics of
Arrhythmia Therapy (PAT) Center of PGRN is that
susceptibility to spontaneous cardiac arrhythmias, as well as
those induced by exposure to certain drugs, may be
associated with inherited polymorphisms in genes involved
with this complex phenotype. Defining the genetic associa-
tions of antiarrhythmics may allow identification of the high-
risk patient, as well as define the most effective and least toxic
therapy.
Findings and future directions. Among PAT’s current
studies of pharmacogenetics of arrhythmia generation and
treatment are two distinct foci: control of the QT interval and
studies of AF.
Reduction in cardiac sodium current either by drugs22 or
as a result of loss of function in the sodium channel gene,
SCN5A,23,24 predisposes to ventricular fibrillation. Recent
studies identified multiple variants with altered promoter
activity in SCN5A. Notably, a common set of linked
polymorphisms was identified in Asian subjects, with a
minor allele frequency of B25%.25,26 The variant haplotype
displays markedly reduced promoter activity in vitro, but also
predicts QRS duration (an electrocardiogram index of
sodium channel function) at baseline and during a challenge
with sodium-channel-blocking drugs. Identifying interspecies
conserved nucleotide sequences and noting variations in
these conserved areas may identify additional polymorphisms
in candidate genes that regulate SCN5A expression.
Screening another gene, KCNA5, which regulates human
atrial potassium current IKur, has revealed new coding region
polymorphisms.27,28 Notably, a polymorphism resulting in
P532L (minor allele frequency 2% in African American
subjects) in the C terminus generated a potassium current
that was unexpectedly associated with resistance to drug
therapy. Of note, structural studies identified a probable
a-helix in P532L, absent in wild-type channels. Further,
structural data support a model where an a-helix impairs
access of the drug to a pore-binding site. Variants in KCNA5
are now being described in AF.
Evolving from these studies, the effort of PAT can be
divided into three overall goals. First, candidate genes are
screened for variants and then function is characterized in
heterologous expression systems. Second, the genetic deter-
minants of variability in the response of the QT interval to
drug challenge are evaluated. To accomplish this, large
numbers of subjects with well-phenotyped responses to
QT-prolonging drugs are systematically accumulated. DNA
samples are screened for variants in the relevant genes. In
addition, new genes modulating the response to challenge
with QT-prolonging drugs are being sought in a validated
and reproducible assay system using the model organism
Danio rerio (zebrafish). Third, genetic determinants of drug
response in AF provide another arena to define genetic
contribution to a complex clinical phenotype. Two databases
are being developed; one including patients and kindreds
with AF, and the other including subjects undergoing cardiac
surgery, as 20% develop AF postoperatively. These data sets
of clinical profile plus DNA samples can then be screened for
variants with high-throughput methods. Applying high-
throughput genomic analyses to DNA samples that can be
correlated to highly characterized clinical data constitutes the
major strategy that PAT is pursuing to both identify the
genetic component of risk for the various arrhythmias as well
as to contribute to rational drug therapy.
Pharmacogenomics of Antiplatelet Therapy Intervention
Introduction. Of those who die suddenly from coronary
heart disease (CHD), 50% of men and 64% of women have
no previous symptoms. This clinical observation, coupled
with an increased appreciation of the interdependence of
atherosclerosis, inflammation, and thrombosis, have led to
the conclusion that platelet aggregation and thrombosis are
major factors leading to vasculo-occlusive or atherothrom-
botic events. Antiplatelet agents such as aspirin and
clopidogrel are effective for primary and secondary preven-
tion of coronary events; decreasing incidence rates of
myocardial infarction by approximately 20–25%. However,
numerous studies indicate that there is substantial variability
in response to antiplatelet agents with up to 30% of subjects
considered nonresponders to aspirin,29,30 and 25% of subjects
considered to nonresponders to clopidogrel.31–34 The ability
to predict which individuals will respond to and which will
be resistant to antiplatelet therapy would have a profound
impact on the prevention and treatment of CHD and would
benefit millions of Americans with CHD or those who are at
risk for CHD.
Goals. The mechanism underlying interindividual variabil-
ity in response to antiplatelet agents is not known. However,
evidence supports an important genetic component. The goal
of the pharmacogenomics of antiplatelet therapy intervention
(PAP) group, one of the three new groups in the PGRN, is to
identify specific gene variants that predict response to aspirin
and clopidogrel therapy.
Future directions. Studies in pharmacogenomics of anti-
platelet therapy intervention are being conducted in the Old
Order Amish of Lancaster, Pennsylvania, a genetically
homogeneous closed founder population ideal for genetic
studies. The Amish Heredity and Phenotype Intervention
(HAPI) Heart Study is part of the NHLBI-funded PROgram
for GENetic Interaction Network and was designed to
examine gene–environment interactions in defining risk for
CHD. A total of 868 healthy Amish subjects from large
families were recruited for HAPI.
Currently, members of the Amish HAPI Heart Study are
being recalled for entry into the pharmacogenomics of
antiplatelet therapy intervention study. The study design will
evaluate response to clopidogrel alone and clopidogrel plus
aspirin. Candidate gene and genome-wide association studies
will be conducted to identify the genetic underpinnings of
interindividual variation in response to these antiplatelet
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agents. Specifically, the studies will: (1) determine the
frequency and heritability of clopidogrel response and the
relationship between clopidogrel resistance and aspirin
resistance; (2) exhaustively define sequence variation and
haplotype structure of 100 candidate genes and include
association analysis of SNPs/haplotypes with platelet function
phenotypes; and (3) perform genome-wide association
analysis using 500K Affymetrix SNP chips, already available
in all HAPI Heart subjects.
The proposed study will provide important genetic,
molecular, and mechanistic insights into aspirin and
clopidogrel resistance. These insights will lead to diagnostic
testing to identify patients who are clopidogrel- and/or
aspirin-resistant so that more effective therapies can be
prescribed for these individuals. Furthermore, understanding
the molecular underpinnings of clopidogrel and aspirin
resistance will provide mechanistic insights from which new
medications can be designed.
PULMONARY
Pharmacogenetics of Asthma Treatment
Introduction. Although asthma is a common entity affecting
an estimated 300 million individuals worldwide,35 a specific
etiology has not been identified. Treatment modalities vary
and must be adjusted depending on the response of an
individual patient. That is, although the diagnosis of
‘‘asthma’’ implies a common constellation of physical
symptoms and signs, the disease is a complex syndrome
with a spectrum of severity in clinical findings. The response
to treatment of asthma is characterized by marked inter- and
intraindividual variability36–38 and frequent adverse drug
reactions. Available data suggest that genetic factors may
contribute as much as 60–80% to the variability in treatment
response. Such a disease entity provides a model system,
though complicated, to investigate the functional genomics
of candidate gene and whole genome associations.
Goals. Pharmacogenetics of Asthma Treatment (PHAT)
(http://www.pharmgat.org/) has focused on the hypothesis
that genetic determinants of the response to drug therapy for
asthma can be identified and studied in model systems, and
eventually a prognostic genetic test determining responder vs
nonresponder for each class of asthma medication can be
clearly defined. Such a project moves from the ‘‘classic’’
monogenic Mendelian inheritance to the more complicated
arena of variable, complex phenotypes that characterize
asthma and many clinical diseases (e.g., diabetes, hyperten-
sion, depression). PHAT studies three classes of drugs:
b-adrenergic agonists, inhaled corticosteroids, and leukotriene
antagonists.
Findings and future directions. As with many pharmaco-
genetic investigations, PHAT uses multiple approaches to
identify genetic determinants of response to antiasthmatic
drugs. Each approach has particular advantages (see Table 1).
PHAT initially focused on single candidate genes, or small
groups of genes,39–42 including associations of CRHR1,
TBX21, and AC9 with response to inhaled corticosteroids.
Of significance, more recent efforts have expanded to apply a
well-described, family-based screening algorithm to genome-
wide association studies.43 The screening technique identifies
markers with the highest conditional power for association
without biasing any subsequent test statistic.44–46 PHAT
investigators have adapted this approach to current studies
and are currently evaluating 2,013 SNPs in 220 candidate
genes for response to inhaled corticosteroids and b-agonists.
By combining biologic, pathway, and expression array
analyses, variants are identified in candidate genes powered
for association in a population of 464 European-American
trios who were participants in the Childhood Asthma
Management Program clinical trial.47 Genes that indicate
association with pharmacogenetic phenotypes in Childhood
Asthma Management Program are then sequentially explored
in a second and third clinical trial population. Next, genes
with confirmed replications are completely resequenced and
functionally evaluated to characterize the etiologic basis
underlying the association. Finally, upon completion of the
association testing and functional work, the findings are
utilized to develop a predictive model of treatment response,
which will be tested on multiple population samples to assess
its predictive capabilities (see Figure 6). This approach has
been presented in more detail in a recent review.48
This approach strives to address many of the potential
problems inherent in genetic association studies, including
Table 1 Advantages of current asthma pharmacogenetic study design
Technique Advantage How implemented
Screening algorithm Helps address multiple comparisons issues Screen using non-informative families before performing
FBAT analysis
Family-based association test Population stratification is not an issue FBAT testing methodology using probands and parents
Principal components analysis Increases statistical power Each longitudinal outcome measure contributes to the
observations
Replication population testing Helps to assure generalizability and address false
positives
Two population-based replication studies for each gene
identified via screening, before confirmation
Functional studies Extends association studies into the functional
domain
Use of gene expression, in vitro, and animal models to
test specific candidate genes and variants
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multiple comparisons, lack of statistical power, population
stratification, and failure to replicate.48 Moreover, this
group of collaborative investigators is well positioned to
investigate the molecular biology and functional genomics of
any identified associations. To accomplish this, it is essential
to explore variations of the screening algorithm (e.g.,
candidate gene vs candidate SNP approaches) to determine
the optimal combination of sensitivity and specificity.
Extensions of these methods can be readily applied to
planned whole-genome association studies. This current
modification to the approach to identifying the genetic
contribution to response to pharmacotherapy for asthma
marks a striking sophistication to defining the genetics of a
complicated phenotype.
ADDICTION
Pharmacogenetics of Nicotine Addiction and Treatment
Introduction. Tobacco use is arguably the most important
preventable cause of premature disability and death. Smokers
tend to maintain exposure to similar amounts of nicotine, the
psychoactive substance in tobacco, from day to day, so as to
optimize nicotine-mediated reinforcements and to minimize
nicotine withdrawal symptoms. Of note, rapid metabolizers
of nicotine smoke more cigarettes, take in more tobacco
smoke, and have altered responses to treatment medications,
compared with slower metabolizers.49 Nicotine is metabo-
lized to cotinine (COT) primarily via C-oxidation by the liver
enzyme CYP2A6. COT is further metabolized to trans-30-
hydroxycotinine (3HC) by the same enzyme. Although the
rate of metabolism of nicotine by CYP2A6 is highly
correlated with CYP2A6 genotype, variability in nicotine
metabolism remains large among smokers with the func-
tional wild-type allele of CYP2A6. That is, most of the
individual variability in CYP2A6 activity cannot be fully
explained by the current available data about variant alleles of
CYP2A6.50 Validating the nicotine metabolic ratio (3HC/
COT) has introduced a noninvasive, accurate phenotypic
marker of CYP2A6 activity to allow investigation of nicotine
metabolism with smoking behavior.
Goals. The Pharmacogenetics of the Nicotine Addiction
Treatment (PNAT) group, one of the three new PGRN
groups, is investigating the genetic basis of addiction to
tobacco and the variation in response to medications used to
treat tobacco dependence. Genetic risk contributes to various
aspects of smoking, including, for example, persistence in
smoking in spite of multiple attempts to stop, as well as the
number of cigarettes smoked per day (50% genetic
heritability).
Findings and future directions. The impact of four known
and common CYP2A6 alleles (*2, *4, *9, *12) have been
correlated with in vivo metabolism of nicotine and COT,
allowing genotype to predict an average level of nicotine
clearance.51 However, in view of the current incomplete
knowledge about the role of genotype on nicotine metabo-
lism, novel variants (e.g., *14–*22), regulatory variants (e.g.,
*1B), and other completely uncharacterized variants are
under study in well-characterized cohorts of nicotine
delivery.
Designing individualized smoking cessation programs
based on the likelihood of success is a long-term goal of
the Pharmacogenetics of Nicotine Addiction and Treatment
program. The 3HC/COT ratio, measured in the blood of
smokers before nicotine transdermal treatment, was pre-
dictive of outcome. That is, smokers with a low ratio (slow
metabolizers) had a twofold greater smoking cessation
response to nicotine patch treatment than smokers with a
high ratio (rapid metabolizers), suggesting that rapid
metabolizers need higher doses of the nicotine patch.50 In
contrast, when given nicotine spray, which is a titratable
form, those with genetically slow CYP2A6 used fewer sprays
(titrated) and had similar abstinence rates.49,50 Bupropion, a
commonly used smoking cessation drug, is metabolized
predominantly by CYP2B6. CYP2B6 genotype was signifi-
cantly correlated with outcome at the end of treatment,
which was similar at 6-month follow-up. Of interest, the
CYP2B6*4 allele has been associated with an increased 3HC/
COT ratio, implying its role in nicotine as well as in
bupropion metabolism.
Figure 6 Flow chart for the functional evaluation of genes with replicated
associations. Replicated genes from clinical trial populations are explored for
functional basis of genetic effects, using gene expression studies, cellular
models, and animal models (reprinted from: Pharmacogenomics J. 6,
311–326 (2006).
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Thus, by focusing on genotyping a large number of
candidate genes believed to be involved in nicotine addiction
pathways in smokers who have participated in clinical trials
of nicotine replacement or bupropion for smoking cessation,
PNAT aims to comprehensively evaluate the interaction of
genetic factors and pharmacologic interventions via pathway-
based Bayesian hierarchical modeling. Ultimately, this
modeling may predict individual outcomes so that pharma-
cologic interventions for smoking cessation treatment can be
tailored individually.
CANCER
Pharmacogenetics of Anticancer Agents Research
Introduction. Although research over the last decade has led
to new and improved therapies for a variety of different
diseases, anticancer drug therapy continues to have unac-
ceptable outcomes, including both poor response and severe
toxicity. In addition to the critical need to discover new
drugs, it is important to optimize existing drugs to minimize
adverse drug reactions and maximize efficacy.
Goals. Pharmacogenetics of Anticancer Agents Research
(PAAR) investigators primarily follow a phenotype-driven
approach to identify those genetic polymorphisms that are
most important for anticancer drug efficacy and adverse
events. In particular, the group investigates genetic poly-
morphisms in both PK and PD pathways of several anticancer
drugs. In addition, PAAR focuses on the pharmacogenetics of
treatment of childhood acute lymphoblastic leukemia (ALL).
Findings and future directions. PK pathways: Many drugs
that effectively treat adult and pediatric tumors are substrates
for the enzyme CYP3A, and the efflux transporter P-
glycoprotein (ABCB1, MDR1). Cytochrome P450 (CYP)
refers to a complex group of enzymes that catalyze the
metabolism of a large number of endogenous and exogenous
compounds, as well as affect circulating steroid levels and the
response to at least 50% of all oxidatively metabolized drugs.
More than 50 different CYP genes operate in humans, and
these are classified into different families based on sequence
homology. The CYP3A subfamily is the most abundant CYP
in human liver and small intestine. Furthermore, one
member, CYP3A5, is expressed polymorphically, varying
with ethnicity, and contributing significantly to the inter-
individual and interracial differences in drug responses and
clearance. CYP3A5 is also the main CYP3A enzyme expressed
in extra-hepatic tissue, such as intestine, kidney, lung, and
white blood cells.
Identifying that the genetic basis for polymorphic
expression of CYP3A552 is caused by a remarkable intronic
SNP that abolishes expression via creation of an alternative
splice site dramatically influenced general approaches to
pinpointing other molecular mechanisms that explain
variability in drug metabolism. That is, linking an alteration
in splicing to the expression of a gene (in this case, expression
of a specific allele, CYP3A5*1) defined its contribution to
total CYP3A as 50%. This discovery identified a specific
molecular entity that predicted a patient’s ability to clear
substrates of an enzyme and, therefore, also suggested a
possible source of drug–drug interactions. In addition to the
direct impact on pharmacology of drugs dependent on this
metabolic pathway, CYP3A5’s prevalence in renal tissue has
led to investigations of its role in the risk of hypertension.53,54
Although the tactic of linking specific variants in a gene to
change in function of its product has been productive, in
many cases, variability in the gene does not completely
account for a phenotype. For example, cis variability in
CYP3A or PXR (the primary transcription factor for
CYP3A4) genes55,56 does not appear to totally account for
CYP3A activity. Instead, the final expression of the gene must
be more complex and probably depends on variation in the
genotype of trans genes, such as ABCB1 (P-glycoprotein,
MDR1). In fact, MDR1 may predict the basal CYP3A4
expression, and in that way, mediate various drug interac-
tions for substances that are substrates of both CYP3A4 and
MDR1/P-glycoprotein.57,58
Another PK pathway of major relevance to cancer
pharmacotherapy involves glucuronidation, particularly the
UGT1 gene, which is alternatively spliced to produce nine
different glucouronosyltransferases.59 For example, toxicity
after irinotecan, a standard option for relapsed/refractory
advanced colorectal cancer, is inversely correlated with
glucuronidation of its active metabolite, SN-38, by
UGT1A1.60–62 Variability in glucuronidation of SN-38 is
associated with a common polymorphism in the promoter of
UGT1A1. Of significance, this polymorphism is also
associated with the magnitude of myelosuppression coronary
to irinotecan.63,64 This critical finding is directly applicable to
the clinical realm and promptly led to the FDA incorporating
this finding into the package insert of irinotecan. In addition,
a 510(k) diagnostic test for UGT1A1 genotyping is now
available.
PD pathways: Identifying polymorphisms that explain
variability in PDs of anticancer agents is another major aspect
of PAAR’s current investigations. For example, cisplatin
heritability has been of particular interest. A linkage analysis
study of the cytotoxicity of cisplatin using CEPH cell lines
identified clear heritability (0.47), with the strongest linkage
signal on chromosome 1.65 Further studies are ongoing to
identify genes that may be associated with sensitivity and
resistance to cisplatin.
A drug target of particular interest to PAAR is the
epidermal growth factor receptor (EGFR) that includes an
intracellular tyrosine kinase domain, is located on most
epithelial cells and malignant tumors of epithelial cell origin,
and has a critical role in regulating cell proliferation and
differentiation. A class of chemotherapeutic agents has been
developed to treat tumors that overexpress EGFR, which
includeB30% of various primary cancer of the breast, colon
and rectum, lung, prostate, pancreas, head and neck, and
ovary. Overexpression of EGFR implies an adverse disease
stage, poor prognosis, and higher risk for metastases. In part,
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the poor outcome is secondary to lack of response to
chemotherapy or, after an initial response, development of
drug resistance. Of particular challenge in developing rational
drug therapy is the fact that the regulation of EGFR
expression is complex and incompletely defined. In addition,
evidence suggests that overexpression of the EGFR gene
contributes not only to variable response to therapy, but also
to an increased genetic risk for developing cancer.
Response to EGFR inhibitors (i.e., genitinib and eriotinib)
is unpredictable and does not seem to correlate highly with
the level of overexpression, and only a small portion of the
variability can be attributed to somatic mutations.66,67 The
PAAR Group has focused on germline polymorphisms in the
promoter region and intron 1 of EGFR, and has identified a
common functional SNP in an Sp1-binding site in
the promoter.68,69 Of note, binding of Sp1 proteins in the
promoter region is essential to EGFR gene transcription, and
SNPs in this area have been associated with changes in Sp1
binding affinity that may affect gene expression. Of particular
interest to PGRN, marked interethnic variability exists in
some of these variants, which may be associated with
interethnic variability in response to EGFR inhibitors.
Clearly, the molecular mechanisms for variable response as
well as resistance to anti-EGFR therapy is multifactorial (e.g.,
redundant tyrosine kinase receptors, activation of alternative
activators, etc.), but the role of SNPs or haplotypes in the
promoter region may be critical to individualized therapy
with these agents.
ALL: One of the primary disease-oriented pharmacoge-
netic efforts of the PAAR group is childhood ALL, the most
common pediatric malignancy, and a model tumor in that it
is highly curable with medications alone.70 Until recently,
treatment for ALL was initiated based on the presence of
various genetic markers of leukaemia, but without consider-
ing genetic variability of the patient. As in other cancers,
chemotherapy for ALL involves agents with narrow thera-
peutic-to-toxic dose ranges and outcome of ALL may be
affected by modest changes in doses of effective agents.
Clearly, if genetic variation to chemotherapy could be
determined, treatment could be optimized to further improve
cure while avoiding toxicity. In fact, the PAAR group has
identified germline genetic polymorphisms that predict risk
for hematologic relapse; the most common cause of failure of
treatment in ALL.
Based on pathways affecting the drugs used to cure the
disease, the PAAR group has focused on polymorphisms in
genes that code for proteins involved in the metabolism of
antileukemic agents. Several specific enzymes (and their
genes) have been investigated: glutathione transferase
(GSTM1), thymidylate synthase (TYMS), vitamin D receptor
(VDR), and thiopurine methyltransferase (TPMT). Poly-
morphisms that affect GSTM1 and TYMS correlate with the
probability of relapse,71 whereas polymorphisms in VDR and
TYMS correlate with the risk of one of the primary dose-
limiting toxicities of therapy, glucocorticoid-induced osteo-
necrosis.72 In addition, polymorphisms in TPMT have been
associated with drug resistance and may be particularly
relevant to the concept of individualized drug dosages to
avoid toxicity without compromising efficacy (Figure 7).73 A
genome-wide approach has been used to show that germline-
variability affects gene expression,74 that modest differences
in therapy (e.g., high- vs low-dose methotrexate) cause
substantially different effects on gene expression,75 and to
identify novel genetic variation that contributes to drug
resistance ex vivo, which also predicts long-term relapse
risk in vivo in at least two independent clinical trials
(Figure 8).76,77 Because fewer than 5% of genes associated
with resistance were predicted based on a candidate gene
pathway approach, these studies have demonstrated the
critical importance of whole-genome approaches to pharma-
cogenetics.
In cancer, one must consider both germline genetic
variability and the acquired genetic variability of the target
tumor tissue. PAAR group investigators have demonstrated
that the acquired karyotype of the malignancy can create a
discordance between germline pharmacogenetic genotypes
and the genotype of the malignant cells, which can accentuate
or diminish the tumor response relative to host genetic
variability, depending on the allelic distribution of chromo-
somal aberrations in the tumor.78 Thus, outcome after
treatment of ALL is a function of multiple factors: drug
interactions, tumor sensitivity/genetics, and host factors
(including germline variants). Of particular interest to the
PGRN investigations, genetic factors in pediatric patients
with ALL have been identified that in the future may allow
therapy to be intensified in particular patients and relaxed in
others in direct response to pharmacogenetic profiles.
Figure 7 Impact of germline TPMT genotype on incidence of toxicity
(upper). The lower graph indicated that when dose is individualized based
on TMPT germline status, the cumulative incidence (CI) of relapse is not
compromised.
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Consortium on breast cancer pharmacogenomics
Introduction. More than 70% of all breast cancers are
estrogen dependent. Studies over the last 120 years have
demonstrated that strategies that target the interaction of
estrogen with its cellular receptor (the estrogen receptor, ER)
result in dramatic reductions in the morbidity, mortality, and
incidence of this common disease. Several pharmacologic
agents have been shown to be effective endocrine therapies
for breast cancer. These include the selective ER modulator
tamoxifen and agents that inhibit the aromatization of
steroidal precursors into estradiol and estrone (aromatase
inhibitors, AIs) in peripheral tissue in postmenopausal
women. There are two classes of AIs: triazoles (letrozole,
anastrozole) and steroids (exemestane). More recently, a third
category of antiestrogens has been studied: the so-called
selective ER downregulators, for which fulvestrant is the
prototype.
These drugs represent a cornerstone in the treatment of
breast cancer, and they also offer an opportunity to study the
actions of estrogen in women without breast cancer. The wide
variety of pharmacologic strategies to interfere with the
estrogen/ER interaction is an ideal situation to study
pharmacogenomics. Tamoxifen, the AIs, and fulvestrant are
all active against estrogen-receptor-positive breast cancer, but
only incompletely, with benefit rates ranging from 30% to
70%. Furthermore, toxicities are highly variable. For
example, although hot flashes are a common complaint
among treated women, they are not universal (approximately
50–70%). Musculoskeletal complaints occur in approximately
40% of women treated with an AI, and are the reason for
drug discontinuation in approximately 10%. Until recently,
most investigators focused their studies of the variability of
activity on somatic changes within the tumor (such as the
presence or absence of ER or associated molecules). Few, if
any, studies have, investigated the effects of inherited genetic
differences on activity and almost none have addressed
toxicities. Translational research studies of inherited differ-
ences in genes that alter these drugs to active or inactive
metabolites (which represent many different chemical
compounds) and in genes that serve as the targets or
modulators for these agents (such as the aromatases and/or
the ER) are rich areas of opportunity to individualize
therapy.
The Consortium on Breast Cancer Pharmacogenomics
(COBRA) represents a unique collaboration between the
Division of Clinical Pharmacology at Indiana University and
five large breast oncology research groups at NCI-funded
Comprehensive Cancer Centers: Indiana University, Johns
Hopkins University, the Mayo Clinic, University of Michigan,
and Baylor College of Medicine. The considerable, practical
clinical experience in these centers and the remarkable
willingness of patients with breast cancer to contribute to
research has been harnessed to enroll a large number of
patients willing to contribute genetic information and
carefully-curated phenotypes to the PharmGKB. These
include a series of serum biomarkers in response to anti-
estrogen treatments, PK assessments of AI concentrations,
measures of bone density, breast density, hot flashes, and
validated diaries designed to record subjective symptoms that
document psychiatric symptoms and quality of life changes.
Goals. The goals of COBRA are to facilitate studies that test
for associations between variations in candidate genes and
response to treatments for breast cancer. Given the strong
role that anti-estrogens have historically played in the
treatment of breast cancer, COBRA has chosen to focus on
genes in the estrogen metabolism and response pathways and
those that control the activation, distribution, and elimina-
tion of these drugs.
Findings and future directions. The early work of COBRA
demonstrated new routes of activation for tamoxifen that are
under genetic control and identified a new and active
metabolite of tamoxifen, endoxifen. These data showed a
strong association between CYP2D6 polymorphisms and
plasma concentrations of N-desmethyl 4-hydroxy tamoxifen
(‘‘endoxifen’’).78 In the laboratory, CYP2D6 was demon-
strated to catalyze the metabolism of tamoxifen to endoxi-
fen,79 and endoxifen was shown to be as potent an anti-
Figure 8 Whole-genome approach to identify genes that predict survival.
Genes whose expression predicted in vitro drug sensitivity also predicted
probability of disease-free survival in St Jude patients (upper) and
independent group of patients treated on Dutch/CoAll studies (lower).
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estrogen as 4-hydroxy-tamoxifen, previously thought to be
the active form of tamoxifen.80 Endoxifen and 4-hydroxy-
tamoxifen appeared to have almost identical effects as
measured by microarray expression analysis.81 Early clinical
studies demonstrated that women who carry germline-
inactiving SNPs of CYP2D6, such as CYP2D6 *4*4, produce
little or no endoxifen after tamoxifen administration.
Further, CYP2D6 inhibitors, such as the selective serotonin
reuptake inhibitor (SSRIs) paroxetine and fluoxetine,78,82
which are frequently prescribed to breast cancer patients to
treat depression and hot flashes, result in lower concentra-
tions of this active metabolite. As a result, patients are now
routinely advised to avoid CYP2D6 inhibitors while taking
tamoxifen.
To investigate whether this PK observation is clinically
important, COBRA has completed accrual to a prospective
registry of women initiating tamoxifen therapy to study
correlations between several phenotypes (hot flashes, quality
of life, bone mineral density, circulating lipids, weight gain)
and multiple genotypes (CYP2D6, sulfatases, ER, coactiva-
tors, and repressors) will be studied. Importantly, CYP2D6
status will be evaluated to identify any association with
tamoxifen activity against breast cancer.
COBRA investigators have demonstrated that genotyping
CYP2D6 from archived formalin-fixed, paraffin-embedded
breast cancer tissue and from white blood cells from the same
individuals produced identical results. These data were the
basis of a retrospective collaboration with PGRN-funded
investigators from the Mayo Clinic. That is, DNA from
participants enrolled in an earlier prospective trial of
tamoxifen was utilized in an investigation that suggested
that poor metabolizers of tamoxifen (several variants of
CYP2D6) have greater rates of disease recurrence in the
adjuvant setting83 and that CYP2D6 inhibitors mimic this
effect.84,85 The FDA is considering changing the label of
tamoxifen to include the link between CYP2D6 genotype and
activation/response to tamoxifen. Although these data are
clinically significant for certain patients, investigators in
COBRA are sensitive to the concern that this single retro-
spective study should not lead to the general practice of
withholding tamoxifen in favor of other drugs, such as the
AIs. This newer class of agent has a different mechanism of
action, distinct activity and toxicity profiles, and cannot be
used in premenopausal women. Thus, COBRA has initiated a
large number of collaborations with the NCI cooperative
groups and with the large international trial community to
validate the utility of CYP2D6 genotyping for patients
considering tamoxifen therapy using archived formalin-fixed,
paraffin-embedded tissue.
The increasing importance of the AIs in the treatment and
prevention of breast cancer is clear. Thus, in addition to the
ongoing prospective and retrospective studies of tamoxifen,
COBRA has initiated a prospective randomized clinical trial
to compare the pharmacogenomics of agents from the two
classes of AIs (letrozole and exemestane) in postmenopausal
breast cancer patients in the adjuvant setting. DNA will be
collected to perform pharmacogenetic studies that can then
be correlated with a large number of curated phenotypes to
potentially identify biomarkers of response. Moreover,
COBRA is collaborating with other investigators to study
the pharmacogenomics of selected candidate genes involved
in metabolism and activity of anastrozole and fulvestrant.
Comprehensive research on expressed alleles in therapeutic
evaluation
Introduction. Similar to most common diseases, the clinical
response to a medication is under the control of a network of
genes (i.e., polygenic trait), each contributing to the patient’s
phenotype, in this case, drug response. Comprehensive
Research on Expressed Alleles in Therapeutic Evaluation
(CREATE) aims to identify common polymorphisms in
various drug response pathway genes most relevant to
association studies, concentrating on the multispecies con-
served sequences. Then, by using computational biology
approaches to evaluate the identified variants, the goal is to
predict functional importance. The identified variants are
correlated with common ethnic/racial groups.
Goals. A central challenge in pharmacogenetic studies is
selecting the ‘‘right’’ genes to study to improve clinical
decision-making in the setting of variability in response to
drug therapy. Constructing drug response pathways has
provided a framework to prioritize candidate gene investiga-
tions as well as a method to then increase the comprehensive
impact of SNP/haplotype discovery on maximizing appro-
priate drug choice across diverse groups of patients. To
accomplish its investigations, CREATE has interacted with
several groups of the PGRN network: PAAR, Pharmaco-
genetics of Membrane Transporter (PMT), and COBRA.
Findings and future directions. The concept that multiple
subpopulations exist within a cohort of patients with a
diagnosis of breast or colon (and other) cancer is well
recognized. However, focusing on pathways of pharma-
cologically relevant proteins to define drug response in
such clinical settings is novel. Three variations of this
emphasis on pathways rather than individual genes have
led to innovative views of individualized therapy for cancer
by the CREATE group. First, the CREATE group recently
evaluated the irinotecan (topoisomerase I inhibitor used to
treat colorectal, lung, cervical, and esophageal cancers)
pathway in a spectrum of common tumors. Of note,
irinotecan’s metabolism is complicated, with contributions
from a wide variety of enzymes that define not only efficacy,
but also toxicity. After studying 255 tumors with 11
predefined markers, two distinct patient groups were
identified.86 The data demonstrate that patients with
lymphoma, melanoma, and brain, colon, breast, as well as
ovarian, and prostate cancer have the same pharmacologic
profile with distinct homogeneity in sensitivity to irinotecan.
This sets the stage for further investigation into anatomy-
independent therapy of cancer.
340 VOLUME 81 NUMBER 3 | MARCH 2007 | www.nature.com/cpt
STATE ART
A second view of pharmacologic profiles was established
in a study of polymorphism discovery in 51 chemotherapy
pathway genes of nine commonly used anticancer agents,
sampling three different ethnic populations (African Amer-
ican, Asian Americans, and European Americans).87 Of note,
346 novel variants were identified in this focused resequen-
cing project. From these data, a more comprehensive set of
polymorphisms was generated that will be important to
consider in defining therapeutic response and toxicity
targeted as a function of specific ethnic groups.
The third focus on pathways evaluated DNA repair and
microsatellite instability in one specific cancer, Dukes’ C
colorectal.88 Instead of evaluating a specific DNA repair gene,
the mRNA expression level of 20 DNA repair pathway genes
were evaluated together. The variability identified again
emphasizes that predicting outcome and response to
chemotherapy results from the interplay of multiple genes.
Thus, these and future investigations of pharmacologic
pathways advance the possibility for selecting the ‘‘best’’
patients for a given drug or combination therapy, increasing
efficiency, and decreasing toxicity for groups of patients as
well as for individuals with variant genetics.
TRANSPORT
This section describes the Pharmacogenetics of Membrane
Transporters (PMT) project and the Genetics of Response to
Antidepressants (GRAD) project, a subproject within PMT.
Pharmacogenetics of Membrane Transporters
Introduction. Membrane transporters are of great pharma-
cological importance as they provide the target for many
commonly used prescription medications and are a major
determinant of the absorption, distribution, and elimination
of a large number of clinically used drugs. In humans and
other mammals, there are two major superfamilies of
membrane transporters: (1) the solute carrier superfamily
(SLC); and (2) the ATP-binding cassette superfamily (ABC).
SLC transporters are primarily facilitated influx pumps,
whereas ABC transporters are ATP-dependent efflux
pumps.89,90 In many cases, SLC and ABC transporters work
in concert to regulate systemic and intracellular drug levels.
Goals. The overall goal of the PMT project is to understand
how genetic variation in membrane transporters contributes
to variation in drug response. The first step in the genotype-
to-phenotype strategy used by PMT investigators is to
identify common and rare sequence variants in SLC and
ABC membrane transporter genes in ethnically diverse
populations. Nonsynonymous and promoter sequence vari-
ants are then phenotypically characterized in cellular systems.
Finally, the biological relevance of functionally significant
membrane transporter variants in determining drug response
is investigated.
Findings and future directions. Deep resequencing of the
coding and flanking intronic regions of almost 50 membrane
transporter genes by the PMT project has led to the discovery
of many new variants in ethnically diverse US populations.
Statistical genetic analysis of membrane transporter sequence
variant data indicates that for the majority of transporters
there is a three- to fourfold enrichment of variants at
synonymous sites than at nonsynonymous sites and that
high-frequency variants are less likely to change an
evolutionarily conserved amino acid in the transporter
sequence.91,92 These findings suggest that there is selective
pressure against significant changes in transporter sequence,
and therefore function, and support an important role for
ABC and SLC membrane transporters in human fitness.
PMT investigators have pioneered efforts to functionally
characterize amino-acid variants of membrane transporters.
The functional analysis of 88 protein-altering variants of
transporters from the SLC22A, SLC28A, and SLC29A families
has provided insight into the effect of the alteration of an
amino acid on the function of a transport protein.93 Twenty
two variants resulted in more than a 40% decrease in
transport function, with 14 of these showing an almost
complete loss of function (o20%). Both the degree of
chemical change of the amino acid and evolutionary
conservation predicted the impact of a protein-altering
variation on transporter function. An allele frequency
distribution that is skewed toward lower frequencies was
found for variants that decreased function, as well as for
variants at evolutionarily conserved sites that retain function,
providing strong support of selective pressure.93 An im-
portant consideration for using these functional data in
clinical association studies is that substrate-specific effects on
transporter function were noted for several variants.93
Resequencing and cellular phenotyping efforts by PMT
investigators are continuing, with a current emphasis on
understanding, the extent and functional significance of
genetic variation in non-coding regions, especially promoter
regions of membrane transporter genes. Computational
methods are also being developed to aid in the prediction
of the functional consequences of amino acid-altering
variants. The important question of whether genetic poly-
morphisms in membrane transporters influence drug re-
sponse or toxicity is an emerging focus of PMT. Clinical
questions are being addressed both in genotype-to-pheno-
type studies in healthy subjects and in phenotype-to-
genotype studies in relevant patient populations. An
increased understanding of the role of membrane transpor-
ters in drug response pathways will emerge from these
continued efforts by PMT investigators and their PGRN
colleagues.
Genetic Responses to Antidepression
Introduction. Medications belonging to the selective sera-
tonic reuptake inhibitor (SSRI) class of antidepressants are
highly effective in the treatment of depression, although
30–40% of individuals with depression fail to respond to the
first SSRI agent that is prescribed. Effectiveness is assessed
after a trial of 6–8 weeks of pharmacotherapy, during which
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interval the individual is at risk for suicide and other negative
outcomes associated with major depression. Currently, there
are no reliable demographic or genetic predictors of response
to these medications.
Goals. The goals of the GRAD study during the first period
of funding of the PGRN were to examine potential
associations between both therapeutic response to and side
effects of SSRI antidepressants and genetic variation in
monoamine membrane transporters, as well as other
candidates directly involved in serotonin production, trans-
mission, or response. A prospective study population of 1,025
adults initiating pharmacotherapy with fluoxetine or parox-
etine for treatment of unipolar depression was recruited from
Kaiser Permanente psychiatric and primary care clinics in
Northern California. Standardized interviews confirmed
DSM-IV major depression and assessed baseline depression
severity, side effects, and potential covariates. Follow-up was
conducted after 4 and 8 weeks to observe treatment response.
The sample was ethnically diverse; African Americans and
Hispanics comprised 15% each of the sample, Asians and
‘‘Others’’ comprised 5% each, and non-Hispanic Whites were
60% of the sample. DNA samples from the patients were
genotyped for functional polymorphisms in candidate genes
involved in serotonin neurotransmission, focusing particu-
larly on variants in the serotonin transporter (SLC6A4),
which is the target of SSRIs. Of particular interest was a
common insertion/deletion polymorphism in the promoter
region of the serotonin transporter (5-HTTLPR) that had
previously shown mixed results in studies of antidepressant
response. The two common alleles of 5-HHTLPR are 14 (or s
(short)), and 16 (or l (long)), with the l allele associated with
increased transcription.94,95
Findings and future directions. There were no differences in
therapeutic response by medication or ethnic group. In linear
regression analyses of change in symptoms of depression
from baseline to 8 weeks following initiation of therapy, the
serotonin transporter-linked promoter region polymorphism
(5-HTTLPR) was not significantly associated with treatment
response (P¼ 0.06). However, in multivariable logistic
regression analysis that compared those who responded
initially but relapsed before 8 weeks (relapse or placebo
response – 9% of sample) with those who had a sustained or
improving response at 8 weeks (sustained response – 72%),
both the 16/16 (l/l) homozygote and 14/16 (s/l) heterozygote
genotypes were associated with a twofold odds of sustained
response to treatment (95% confidence intervals excluded
1.0) compared with the 14/14 (s/s) genotype. Among African
Americans, the s/l and l/l genotypes were associated with over
five times the likelihood of sustained response compared with
the s/s genotype. No association was found between 5-
HTTLPR genotype and sustained response vs nonresponse to
medication (i.e., no significant reduction in symptoms of
depression). There were no other significant associations
between therapeutic response to SSRIs and variants in other
candidate genes. These results suggest that a common
functional variant in the serotonin membrane transporter
may be associated with greater likelihood of a sustained
therapeutic response to fluoxetine and paroxetine, two
common SSRI medications.
Future directions for the GRAD study include new efforts
to identify candidate genes that affect therapeutic response
and side effects in the GRAD sample. Further, all GRAD
participants will be contacted and a standard interview
conducted to determine the effects of antidepressant treat-
ment over the intervening 4–6 years following acute therapy.
In this way, GRAD may be able to identify potential genetic
determinants of the longer-term neurotrophic response to
antidepressants reported in recent studies.
METABOLISM
Pharmacogenetics of Phase II Drug Metabolizing Enzymes
Introduction. Metabolism is often a critical component of
the final clinical effect of a drug. That is, metabolism often
converts drugs to more water-soluble compounds that are
more easily excreted. In addition, in some cases, a drug must
be metabolized to become therapeutically active. Two
categories of metabolic pathways are commonly described:
phase I (oxidation, reduction, hydrolysis) and phase II
(conjugation reactions, such as glucuronidation, sulfation,
and methylation). Many of the well-described pharmacoge-
netic traits have involved drug metabolism (e.g., N-acetyla-
tion and the NAT2 gene). Pharmacogenetics of Phase II Drug
Metabolizing Enzymes (PPII) has focused on Phase II
enzymes. Early studies resulted in the molecular cloning
and characterization of genes encoding a series of methyl-
transferase and sulfotransferase enzymes. The genetic poly-
morphisms in the prototypic pharmacogenomic and
clinically relevant thiopurine S-methyltransferase gene
(TPMT)96 were correlated with low and high activity of the
enzyme and have been shown to directly impact the clinical
use of thiopurine drugs (e.g., 6-mercaptopurine and
azathioprine) and to vary among ethnic groups. Of major
significance is the fact that clinically applicable pharmacoge-
netic tests for the TPMT polymorphism were developed and
are being widely applied in medical practice.
Goals. The PPII has applied a genotype-to-phenotype
strategy that involves resequencing of genes encoding
proteins that catalyze phase II drug metabolism to fully
identify variant alleles. A major focus for PPII has been
characterizing both the functional implications and mechan-
isms responsible for the effects of nonsynonymous coding
SNPs. These SNPs alter the amino-acid sequence of the
encoded protein and are a common cause of pharmaco-
logically relevant functional variation.
Findings and future directions. PPII has now identified
and functionally characterized many polymorphisms, includ-
ing coding SNPs in scores of genes and has studied their
functional implications. Most often, altered function of
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genetically variant allozymes is due to an alteration in protein
quantity.97–100 A striking example of this phenomenon is
provided by the allozyme encoded by the most common
variant allele for TPMT (TPMT*3A). Decreased levels of this
allozyme have been shown to result from a variety of
mechanisms including aberrant folding and accelerated
degradation.101–103 The accelerated degradation of the protein
product of the most common variant allele has been shown
to be associated, at least in part, with molecular chaperones
such as hsp90 and hsp70 that play a role in protein folding
and targeting misfolded proteins for degradation.102
TPMT*3A has also been shown to aggregate and form
‘‘aggresomes’’.103
Recently, PPII has used a yeast genetic system to identify a
series of genes involved in trafficking and targeting TPMT*3A
for degradation and aggregation. These yeast proteins can be
used to identify mammalian homologs to better characterize
pathways involved in the degradation and aggregation of
TPMT*3A and, perhaps, other genetic polymorphisms of
pharmacogenetic importance.
Finally, two major translational pharmacogenomic studies
comprise a major PPII effort that has evolved from the gene
sequencing effort. One is focused on anastrozole, an
Aromatase Inhibitor that is used to treat breast cancer. These
studies are being performed in collaboration with the MD
Anderson Cancer Center, Houston, Texas and with the
COBRA PGRN Center at Indiana University, Indiana. The
other translational study involves escitalopram, a selective
serotonin inhibitor, and is based on a collaboration between
the Department of Psychiatry at the Mayo Clinic and the
University of Arkansas, Little Rock, Arkansas.
This series of studies demonstrates the complementary
nature of basic and translational pharmacogenomic science, and
that the application of discovery science can lead to mechanistic
hypothesis-based studies that serve to increase our under-
standing of biologic mechanisms responsible for clinically
relevant pharmacogenomic effects of proteins such as TPMT.
SUMMARY
The PGRN comprises a group of investigators with various
approaches to ultimately identify genetic variants that
predispose an individual to nonresponse to or toxicity from
drugs. The collective expertise of the network allows for
synergy in developing methods and in populating a knowl-
edgebase in pharmacogenomics. Research in the PGRN is
necessarily diverse to allow for pharmacogenetic studies of
drug therapies across multiple diseases. Thus, the impact of
the PGRN on the field of pharmacogenetics is broad. In this
overview, we have presented the goals and major findings of
each of the groups in the PGRN and described the data and
knowledge contained in the collaborative knowledge base,
PharmGKB. The application of pharmacogenetics to clinical
practice will advance only in the wake of strong, mechanistic
research from multiple groups.104 Research in the PGRN has
already contributed to and will continue to advance the field
of pharmacogenetics.
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